Polymorphisms in promoter region of FAS and FASL gene and risk of gastric cardiac adenocarcinoma
Rong-Miao Zhou
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorNa Wang
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorZhi-Feng Chen
Divison of Cancer Prevention and Control, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorYa-Nan Duan
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorDong-Lan Sun
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorCorresponding Author
Yan Li
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Yan Li, 12 Jiankang Road, Shijiazhuang, 050011, Hebei Province, China. Email: [email protected]Search for more papers by this authorRong-Miao Zhou
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorNa Wang
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorZhi-Feng Chen
Divison of Cancer Prevention and Control, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorYa-Nan Duan
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorDong-Lan Sun
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Search for more papers by this authorCorresponding Author
Yan Li
Department of Molecular Biology, The Fourth Affiliated Hospital of Hebei Medical University, Hebei Province, China
Yan Li, 12 Jiankang Road, Shijiazhuang, 050011, Hebei Province, China. Email: [email protected]Search for more papers by this authorAbstract
Background and Aim: The FAS and FASL system play an important role in regulating apoptotic cell death. This study was designed to investigate the correlation of FAS-1377 G/A, -670 A/G and FASL-844 T/C polymorphisms with susceptibility to gastric cardiac adenocarcinoma in a population of a high-incidence region of Hebei Province.
Methods: FAS-1377 G/A, -670 A/G and FASL-844 T/C polymorphisms were genotyped by polymerase chain reaction–restriction fragment length polymorphism analysis in 262 gastric cardiac carcinoma (GCA) patients and 524 healthy controls.
Results: Family history of upper gastrointestinal cancer (UGIC) might increase the risk of developing GCA (age- and sex-adjusted odds ratio [OR] = 1.38, 95% confidence interval [CI] = 1.02–1.86). The overall allelotype and genotype distributions of FAS-1377 G/A, and FASL-844 T/C polymorphisms in GCA patients did not significantly differ from that in healthy controls (P > 0.05). Compared with individuals with a FAS-670 A/A genotype, individuals with an A/G genotype in a smoker group had a lower risk of developing GCA (age, sex, and family history of UGIC adjusted OR = 0.55, 95% CI = 0.34–0.88). When the genotypes of FAS and FASL single nucleotide polymorphisms (SNP) were combined to analyze, no significant correlation was found between these SNP and the risk for GCA development.
Conclusion: In the high-incidence region of Hebei Province, FAS-1377 G/A and FASL-844 T/C polymorphisms were not associated with the risk of GCA. However, the FAS-670 A/G genotype might decrease the risk of GCA for smoker individuals.
References
- 1 He YT, Hou J, Chen ZF et al. An analysis of gastric cardia cancer incidence in Cixian for 15 years. Chin. J. Public Health 2006; 22: 1434–5.
- 2
Fielding JWL,
Powell J,
Allum WH.
Cancer of the Stomach. London: The Macmillan Press, 1989.
10.1007/978-1-349-10415-4 Google Scholar
- 3 Launoy G, Milan CH, Faivre J, Pienkowski P, Milan CI, Gignoux M. Alcohol, tobacco and oesophageal cancer: effects of the duration of consumption, mean intake and current and former consumption. Br. J. Cancer 1997; 75: 1389–96.
- 4
Yokokawa Y,
Ohta S,
Hou J et al.
Ecological study on the risks of esophageal cancer in Ci-Xian, China: the importance of nutritional status and the use of well water.
Int. J. Cancer
1999; 83: 620–4.
10.1002/(SICI)1097-0215(19991126)83:5<620::AID-IJC9>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- 5 Yang CS. Vitamin nutrition and gastroesophageal cancer. J. Nutr. 2000; 130: 338S–9S.
- 6 Cai L, Yu SZ, Zhang ZF. Helicobacter pylori infection and risk of gastric cancer in Changle County, Fujian Province, China. World J. Gastroenterol. 2000; 6: 374–6.
- 7 Matsha T, Erasmus R, Kafuko AB et al. Human papillomavirus associated with oesophageal cancer. J. Clin. Pathol. 2002; 55: 587–90.
- 8
Lavergne D,
De Villiers EM.
Papillomavirus in esophageal papillomas and carcinomas.
Int. J. Cancer
1999; 80: 681–4.
10.1002/(SICI)1097-0215(19990301)80:5<681::AID-IJC8>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
- 9 Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342–8.
- 10 Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485–95.
- 11 Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 1998; 101: 2579–88.
- 12 O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996; 184: 1075–82.
- 13 Crnogorac-Jurcevic T, Efthimiou E, Capelli P et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001; 20: 7437–46.
- 14 Gartas C, Tohmoa Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Upregulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 1998; 58: 2057–62.
- 15 Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997; 57: 1007–12.
- 16 Bennett MW, O'Connell J, O'Sullivan GC et al. The Fas counterattack in vivo: apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 1998; 160: 5669–75.
- 17 Von Bernstorff W, Spanjaard RA, Chan AK et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999; 125: 73–84.
- 18 Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumorinfiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J. Cancer Res. Clin. Oncol. 2001; 127: 20–6.
- 19 Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 1997; 34: 577–82.
- 20 Sibley K, Rollinson S, Allan JM et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003; 63: 4327–30.
- 21 Wu J, Metz C, Xu X et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J. Immunol. 2003; 170: 132–8.
- 22 Lima L, Morais A, Lobo F, Calais-Da-Silva FM, Calais-Da-Silva FE, Medeiros R. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis. 2008; 11: 94–8.
- 23 Zhang B, Sun T, Xue L et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007; 28: 1067–73.
- 24 Li C, Larson D, Zhang Z et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet. Genomics 2006; 16: 253–63.
- 25 Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl Cancer Inst. 2004; 96: 1030–6.
- 26 Qiu LX, Shi J, Yuan H et al. FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum. Genet. 2009; 125: 431–5.
- 27 Zhang Z, Xue H, Gong W et al. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 2009; 30: 487–93.
- 28 Zhang Z, Qiu L, Wang M, Tong N, Li J, Zhang Z. The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur. J. Hum. Genet. 2009; 17: 1294–303.
- 29 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988; 16: 1215.
- 30 Zhang Z, Wang LE, Sturgis EM et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2006; 12: 5596–602.
- 31 Yang M, Sun T, Wang L et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin. Cancer Res. 2008; 14: 3230–6.
- 32 Crew KD, Gammon MD, Terry MB et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 2007; 28: 2548–51.
- 33 Zhang H, Sun XF, Synnerstad I, Rosdahl I. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J. 2007; 13: 233–7.
- 34 Park SH, Choi JE, Kim EJ et al. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 2006; 54: 303–8.
- 35 Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell. Immunol. 1999; 192: 48–53.
- 36 Bijl M, Horst G, Limburg PC, Kallenberg CG. Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur. J. Clin. Invest. 2001; 31: 550–3.
- 37 Wang M, Wu D, Tan M et al. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem. Genet. 2009; 47: 559–68.
- 38 Ivansson EL, Gustavsson IM, Magnusson JJ et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int. J. Cancer 2007; 121: 2451–7.
- 39 Erdogan M, Karadeniz M, Berdeli A et al. Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J. Endocrinol. Invest. 2007; 30: 411–16.
- 40 Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res. 2007; 27: 991–4.
- 41 Yang S, Miao XP, Zhang XM et al. Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer. Zhonghua Yi Xue Za Zhi 2005; 85: 2132–5.
- 42 Sun T, Zhou Y, Li H et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J. Exp. Med. 2005; 202: 967–74.
- 43 Zhang X, Miao X, Sun T et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J. Med. Genet. 2005; 42: 479–84.
- 44 Ter-Minassian M, Zhai R, Asomaning K et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 2008; 29: 2147–52.
- 45 Kanemitsu S, Ihara K, Saifddin A et al. A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J. Rheumatol. 2002; 29: 1183–8.
- 46 Wu J, Alizadeh BZ, Veen TV, Meijer JW, Mulder CJ, Pena AS. Association of FAS (TNFRSF6)-670 gene polymorphism with villous atrophy in coeliac disease. World J. Gastroenterol. 2004; 10: 717–20.
Citing Literature
